{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:46:52Z","timestamp":1740138412553,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12020-022-03007-w","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T18:05:11Z","timestamp":1644948311000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mini-review: pump therapy in endocrinology & metabolism beyond diabetes"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1382-2439","authenticated-orcid":false,"given":"Bur\u00e7ak Cavnar","family":"Helvac\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2959","authenticated-orcid":false,"given":"H\u00fcsniye","family":"Ba\u015fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-8827","authenticated-orcid":false,"given":"Bekir","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"issue":"6","key":"3007_CR1","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13300-020-00831-z","volume":"11","author":"J Kesavadev","year":"2020","unstructured":"J. Kesavadev, B. Saboo, M.B. Krishna, G. Krishnan, Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther. 11(6), 1251\u20131269 (2020). https:\/\/doi.org\/10.1007\/s13300-020-00831-z","journal-title":"Diabetes Ther."},{"issue":"2-3","key":"3007_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejphar.2007.11.073","volume":"583","author":"SL Lightman","year":"2008","unstructured":"S.L. Lightman, C.C. Wiles, H.C. Atkinson, D.E. Henley, G.M. Russell, J.A. Leendertz et al. The significance of glucocorticoid pulsatility. Eur. J. Pharmacol. 583(2-3), 255\u2013262 (2008). https:\/\/doi.org\/10.1016\/j.ejphar.2007.11.073","journal-title":"Eur. J. Pharmacol."},{"issue":"1 Pt 1","key":"3007_CR3","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1152\/ajpendo.1989.257.1.E6","volume":"257","author":"JD Veldhuis","year":"1989","unstructured":"J.D. Veldhuis, A. Iranmanesh, G. Lizarralde, M.L. Johnson, Amplitude modulation of a burstlike mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am. J. Physiol. 257(1 Pt 1), E6\u2013E14 (1989). https:\/\/doi.org\/10.1152\/ajpendo.1989.257.1.E6","journal-title":"Am. J. Physiol."},{"issue":"3","key":"3007_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/bf03348128","volume":"10","author":"M Follenius","year":"1987","unstructured":"M. Follenius, C. Simon, G. Brandenberger, P. Lenzi, Ultradian plasma corticotropin and cortisol rhythms: time-series analyses. J. Endocrinological Investig. 10(3), 261\u2013266 (1987). https:\/\/doi.org\/10.1007\/bf03348128","journal-title":"J. Endocrinological Investig."},{"issue":"7","key":"3007_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s2213-8587(13)70182-7","volume":"2","author":"S Lightman","year":"2014","unstructured":"S. Lightman, J.R. Terry, The importance of dynamic signalling for endocrine regulation and drug development: relevance for glucocorticoid hormones. Lancet Diabetes Endocrinol. 2(7), 593\u2013599 (2014). https:\/\/doi.org\/10.1016\/s2213-8587(13)70182-7","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"3007_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1210\/jc.2014-3809","volume":"100","author":"A Mallappa","year":"2015","unstructured":"A. Mallappa, N. Sinaii, P. Kumar, M.J. Whitaker, L.A. Daley, D. Digweed et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 100(3), 1137\u20131145 (2015). https:\/\/doi.org\/10.1210\/jc.2014-3809","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3007_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12020-020-02552-6","volume":"72","author":"C Krekeler","year":"2021","unstructured":"C. Krekeler, P. Kropp, A.K. Blacha, A.H. Rahvar, B. Harbeck, Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep. Endocrine 72(1), 223\u2013233 (2021). https:\/\/doi.org\/10.1007\/s12020-020-02552-6","journal-title":"Endocrine"},{"issue":"1","key":"3007_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1530\/eje-07-0052","volume":"157","author":"K L\u00f8v\u00e5s","year":"2007","unstructured":"K. L\u00f8v\u00e5s, E.S. Husebye, Continuous subcutaneous hydrocortisone infusion in Addison\u2019s disease. Eur. J. Endocrinol. 157(1), 109\u2013112 (2007). https:\/\/doi.org\/10.1530\/eje-07-0052","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"3007_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1210\/jc.2013-4253","volume":"99","author":"M Oksnes","year":"2014","unstructured":"M. Oksnes, S. Bj\u00f6rnsdottir, M. Isaksson, P. Methlie, S. Carlsen, R.M. Nilsen et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison\u2019s disease: a randomized clinical trial. J. Clin. Endocrinol. Metab. 99(5), 1665\u20131674 (2014). https:\/\/doi.org\/10.1210\/jc.2013-4253","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"3007_CR10","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1210\/jc.2014-2433","volume":"99","author":"L Gagliardi","year":"2014","unstructured":"L. Gagliardi, M.A. Nenke, T.R. Thynne, J. von der Borch, W.A. Rankin, D.E. Henley et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison\u2019s disease: a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99(11), 4149\u20134157 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2433","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3007_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/cen.12670","volume":"83","author":"S Bj\u00f6rnsdottir","year":"2015","unstructured":"S. Bj\u00f6rnsdottir, M. \u00d8ksnes, M. Isaksson, P. Methlie, R.M. Nilsen, S. Hustad et al. Circadian hormone profiles and insulin sensitivity in patients with Addison\u2019s disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy. Clin. Endocrinol. 83(1), 28\u201335 (2015). https:\/\/doi.org\/10.1111\/cen.12670","journal-title":"Clin. Endocrinol."},{"key":"3007_CR12","doi-asserted-by":"publisher","first-page":"150005","DOI":"10.1530\/edm-15-0005","volume":"2015","author":"A Khanna","year":"2015","unstructured":"A. Khanna, R. Khurana, A. Kyriacou, R. Davies, D.W. Ray, Management of adrenocortical insufficiency with continuous subcutaneous hydrocortisone infusion: long-term experience in three patients. Endocrinol., Diabetes Metab. Case Rep. 2015, 150005 (2015). https:\/\/doi.org\/10.1530\/edm-15-0005","journal-title":"Endocrinol., Diabetes Metab. Case Rep."},{"issue":"2","key":"3007_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12020-018-1780-4","volume":"63","author":"F Cardini","year":"2019","unstructured":"F. Cardini, E. Torlone, V. Bini, A. Falorni, Continuous subcutaneous hydrocortisone infusion in a woman with secondary adrenal insufficiency. Endocrine 63(2), 398\u2013400 (2019). https:\/\/doi.org\/10.1007\/s12020-018-1780-4","journal-title":"Endocrine"},{"issue":"3","key":"3007_CR14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12020-021-02649-6","volume":"71","author":"H Nowotny","year":"2021","unstructured":"H. Nowotny, S.F. Ahmed, S. Bensing, J.G. Beun, M. Br\u00f6samle, I. Chifu et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine 71(3), 586\u2013594 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02649-6","journal-title":"Endocrine"},{"issue":"1","key":"3007_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2265.2006.02544.x","volume":"65","author":"Z Merza","year":"2006","unstructured":"Z. Merza, A. Rostami-Hodjegan, A. Memmott, A. Doane, V. Ibbotson, J. Newell-Price et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin. Endocrinol. 65(1), 45\u201350 (2006). https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02544.x","journal-title":"Clin. Endocrinol."},{"issue":"9","key":"3007_CR16","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1210\/jc.2009-0630","volume":"94","author":"SM Bryan","year":"2009","unstructured":"S.M. Bryan, J.W. Honour, P.C. Hindmarsh, Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J. Clin. Endocrinol. Metab. 94(9), 3477\u20133480 (2009). https:\/\/doi.org\/10.1210\/jc.2009-0630","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7-8","key":"3007_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1515\/jpem.2011.226","volume":"24","author":"G Tuli","year":"2011","unstructured":"G. Tuli, I. Rabbone, S. Einaudi, V. di Gianni, D. Tessaris, E. Gioia et al. Continuous subcutaneous hydrocortisone infusion (CSHI) in a young adolescent with congenital adrenal hyperplasia (CAH). J. Pediatr. Endocrinol. Metab.: JPEM 24(7-8), 561\u2013563 (2011). https:\/\/doi.org\/10.1515\/jpem.2011.226","journal-title":"J. Pediatr. Endocrinol. Metab.: JPEM"},{"key":"3007_CR18","doi-asserted-by":"publisher","first-page":"219494","DOI":"10.5402\/2011\/219494","volume":"2011","author":"E Sonnet","year":"2011","unstructured":"E. Sonnet, N. Roudaut, V. Kerlan, Results of the prolonged use of subcutaneous continuous infusion of hydrocortisone in a man with congenital adrenal hyperplasia. ISRN endocrinology 2011, 219494 (2011). https:\/\/doi.org\/10.5402\/2011\/219494","journal-title":"ISRN endocrinology"},{"issue":"4","key":"3007_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/cen.13813","volume":"89","author":"A Mallappa","year":"2018","unstructured":"A. Mallappa, A.A. Nella, N. Sinaii, H. Rao, V. Gounden, A.F. Perritt et al. Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia. Clin. Endocrinol. 89(4), 399\u2013407 (2018). https:\/\/doi.org\/10.1111\/cen.13813","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"3007_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1530\/eje-08-0269","volume":"159","author":"M Puig-Domingo","year":"2008","unstructured":"M. Puig-Domingo, G. D\u00edaz, J. Nicolau, C. Fern\u00e1ndez, S. Rueda, I. Halperin, Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. Eur. J. Endocrinol. 159(5), 653\u2013657 (2008). https:\/\/doi.org\/10.1530\/eje-08-0269","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"3007_CR21","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1210\/jc.2011-1359","volume":"96","author":"A Linglart","year":"2011","unstructured":"A. Linglart, A. Rothenbuhler, I. Gueorgieva, P. Lucchini, C. Silve, P. Bougn\u00e8res, Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism. J. Clin. Endocrinol. Metab. 96(11), 3308\u20133312 (2011). https:\/\/doi.org\/10.1210\/jc.2011-1359","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"3007_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000479867","volume":"89","author":"V Saraff","year":"2018","unstructured":"V. Saraff, A. Rothenbuhler, W. H\u00f6gler, A. Linglart, Continuous subcutaneous recombinant parathyroid hormone (1-34) infusion in the management of childhood hypoparathyroidism associated with malabsorption. Horm. Res. paediatrics 89(4), 271\u2013277 (2018). https:\/\/doi.org\/10.1159\/000479867","journal-title":"Horm. Res. paediatrics"},{"issue":"9","key":"3007_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3109\/09513590.2013.813473","volume":"29","author":"J Ilany","year":"2013","unstructured":"J. Ilany, I. Vered, O. Cohen, The effect of continuous subcutaneous recombinant PTH (1-34) infusion during pregnancy on calcium homeostasis - a case report. Gynecol. Endocrinol. 29(9), 807\u2013810 (2013). https:\/\/doi.org\/10.3109\/09513590.2013.813473","journal-title":"Gynecol. Endocrinol."},{"issue":"2","key":"3007_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5606\/tftrd.2019.2718","volume":"65","author":"Z Pekkolay","year":"2019","unstructured":"Z. Pekkolay, F. K\u0131l\u0131n\u00e7, H. Soylu, B. Balsak, M. G\u00fcven, \u015e. Altun Tuzcu et al. Alternative treatment of resistant hypoparathyroidism by intermittent infusion of teriparatide using an insulin pump: a case report. Turkish J. Phys. Med. Rehab. 65(2), 198\u2013201 (2019). https:\/\/doi.org\/10.5606\/tftrd.2019.2718","journal-title":"Turkish J. Phys. Med. Rehab."},{"issue":"3","key":"3007_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","volume":"165","author":"KK Winer","year":"2014","unstructured":"K.K. Winer, K.A. Fulton, P.S. Albert, G.B. Cutler Jr., Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J. Pediatr. 165(3), 556\u2013563 (2014). https:\/\/doi.org\/10.1016\/j.jpeds.2014.04.060. e1","journal-title":"J. Pediatr."},{"issue":"2","key":"3007_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jc.2011-1908","volume":"97","author":"KK Winer","year":"2012","unstructured":"K.K. Winer, B. Zhang, J.A. Shrader, D. Peterson, M. Smith, P.S. Albert et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized cross-over trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(2), 391\u2013399 (2012). https:\/\/doi.org\/10.1210\/jc.2011-1908","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3007_CR27","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra, W. van Biesen et al. European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173(2), G1\u2013G20 (2015). https:\/\/doi.org\/10.1530\/eje-15-0628","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3007_CR28","doi-asserted-by":"publisher","first-page":"155798831881828","DOI":"10.1177\/1557988318818280","volume":"13","author":"L Zhang","year":"2019","unstructured":"L. Zhang, K. Cai, Y. Wang, W. Ji, Z. Cheng, G. Chen et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. Am. J. Men\u2019s Health 13(1), 1557988318818280 (2019). https:\/\/doi.org\/10.1177\/1557988318818280","journal-title":"Am. J. Men\u2019s Health"},{"issue":"3","key":"3007_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14341\/probl12421","volume":"66","author":"MA Melikyan","year":"2020","unstructured":"M.A. Melikyan, D.N. Gubaeva, M.A. Kareva, [Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism]. Probl. Endokrinologii 66(3), 81\u201387 (2020). https:\/\/doi.org\/10.14341\/probl12421","journal-title":"Probl. Endokrinologii"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03007-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T10:52:55Z","timestamp":1651661575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03007-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}